BMS tops Street, halts Opdivo head/neck trial early

Bristol-Myers Squibb Co. (NYSE:BMY) reported 4Q15 and 2015 financial results that beat estimates and said a Phase III trial of Opdivo nivolumab to treat squamous cell carcinoma of the head and neck (SCCHN) was stopped early after meeting the primary overall survival (OS) endpoint.

The open-label CheckMate -141 study compared the mAb against PD-1 vs. investigator's choice of therapy in 361 patients with recurrent or metastatic platinum-refractory SCCHN. ...